首页> 美国卫生研究院文献>Frontiers in Immunology >Toll-Like Receptors and Prostate Cancer
【2h】

Toll-Like Receptors and Prostate Cancer

机译:收费受体和前列腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prostate cancer is the second leading cause of cancer-related death in men after lung cancer. Immune responses clearly play a critical role in the tumorigenesis and in the efficacy of radiation therapy and chemotherapy in prostate cancer; however, the underlying molecular mechanisms are still poorly understood. Toll-like receptors (TLRs) are a well-known family of pattern recognition receptors that play a key role in host immune system. Recent studies demonstrate that there are links between TLRs and cancer; however, the function and biological importance of TLRs in prostate cancer seems complex. To elucidate the role of TLRs and innate immunity in prostate cancer might provide us with a better understanding of the molecular mechanisms of this disease. Moreover, utilizing the agonists or antagonists of TLRs might represent a promising new strategy against prostate cancer. In this review, we summarize recent advances on the studies of association between TLR signaling and prostate cancer, TLR polymorphisms and prostate cancer risk, and provide some insights about TLRs as potential targets for prostate cancer immunotherapy.
机译:前列腺癌是继肺癌之后男性癌症相关死亡的第二大主要原因。免疫反应显然在前列腺癌的发生,放射治疗和化学疗法的功效中起着至关重要的作用。然而,潜在的分子机制仍然知之甚少。 Toll样受体(TLR)是模式识别受体的知名家族,在宿主免疫系统中起关键作用。最近的研究表明,TLR和癌症之间存在联系。但是,TLR在前列腺癌中的功能和生物学重要性似乎很复杂。阐明TLR和先天免疫在前列腺癌中的作用可能使我们对这种疾病的分子机制有更好的了解。此外,利用TLRs的激动剂或拮抗剂可能代表了一种有前途的抗前列腺癌新策略。在这篇综述中,我们总结了有关TLR信号与前列腺癌,TLR多态性和前列腺癌风险之间关系的最新研究进展,并提供了有关TLR作为前列腺癌免疫治疗潜在靶点的一些见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号